A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Richard Wilson, Professor
Centre for Cancer Research and Cell Biology, Queen's University Belfast
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Centre for Cancer Research and Cell Biology, Queen'S University Belfast
Belfast, County Antrim, United Kingdom
- Dept Medical Oncology, the Christie Nhs Foundation Trust
Manchester, Lancashire, United Kingdom
- Freeman Hospital, Northern Centre for Cancer Care, Sir Bobby Robson Cancer Trial Research Centre
Newcastle, Northumberland, United Kingdom
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Apr 2015
- Primary completion
- 13 Mar 2017
- Completion
- 13 Mar 2017
- Last update posted
- 11 Sept 2019
- Registered enrollment
- 20
- Registry id
- NCT03427073
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.